NCT06596759 Diaphragmatic Breathing for the Treatment of Bloating and Distension
| NCT ID | NCT06596759 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Bloating |
| Study Type | INTERVENTIONAL |
| Enrollment | 35 participants |
| Start Date | 2024-10-21 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 35 participants in total. It began in 2024-10-21 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy of diaphragmatic breathing using the validated Mayo Bloating Questionnaire.
Eligibility Criteria
Inclusion Criteria: * Referred for breath testing for the indication of bloating. Exclusion Criteria: * Not referred for breath testing for the indication of bloating.
Contact & Investigator
Brian E Lacy, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06596759 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bloating. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06596759 currently recruiting?
Yes, NCT06596759 is actively recruiting participants. Contact the research team at chase.robert@mayo.edu for enrollment information.
Where is the NCT06596759 trial being conducted?
This trial is being conducted at Jacksonville, United States.
Who is sponsoring the NCT06596759 clinical trial?
NCT06596759 is sponsored by Mayo Clinic. The principal investigator is Brian E Lacy, MD at Mayo Clinic. The trial plans to enroll 35 participants.